AT7519 HCl is primarily used in research settings as a potent inhibitor of cyclin-dependent kinases (CDKs). These enzymes play a crucial role in regulating the cell cycle, and their dysregulation is often associated with cancer. By inhibiting CDKs, AT7519 HCl can induce cell cycle arrest and promote apoptosis in cancer cells, making it a valuable tool in studying cancer biology and developing potential anti-cancer therapies. It is particularly investigated for its efficacy in treating various malignancies, including hematologic cancers and solid tumors, both in preclinical models and early-phase clinical trials. Researchers also explore its potential in combination with other therapeutic agents to enhance anti-tumor effects.